Shares of Brookdale Senior Living, Inc. (NYSE:BKD) ended Tuesday session in red amid volatile trading. The shares closed down -0.01 points or -0.06% at $17.34 with 1.79 million shares getting traded. Post opening the session at $17.26, the shares hit an intraday low of $17.16 and an intraday high of $17.49 and the price vacillated in this range throughout the day. The company has a market cap of $3.19 billion and the numbers of outstanding shares have been calculated to be 185.91 million shares.
Brookdale Senior Living, Inc. (BKD) owns and operates senior living communities in the United States. It operates through five segments: Retirement Centers, Assisted Living, Continuing Care Retirement Centers (CCRCs) Rental, Brookdale Ancillary Services, and Management Services. The Retirement Centers segment owns or leases communities comprising independent living and assisted living units in a single community that are primarily designed for middle to upper income senior citizens. The Assisted Living segment owns or leases communities consisting of freestanding, multi-story communities, and freestanding single story communities, which offer housing and 24-hour assistance with activities of daily life to mid-acuity frail and elderly residents.
Shares of Paratek Pharmaceuticals Inc (NASDAQ:PRTK) ended Tuesday session in green amid volatile trading. The shares closed up +0.02 points or +0.15% at $13.43 with 68,449.00 shares getting traded. Post opening the session at $13.41, the shares hit an intraday low of $13.35 and an intraday high of $13.64 and the price vacillated in this range throughout the day. The company has a market cap of $301.43 million and the numbers of outstanding shares have been calculated to be 22.63 million shares.
Paratek Pharmaceuticals Inc (PRTK), a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics based upon tetracycline chemistry in the United States. Its lead product candidates include Omadacycline, a broad-spectrum, intravenous, and oral antibiotic, which is in Phase III clinical for use as a monotherapy antibiotic for acute bacterial skin and skin structure infections (ABSSSI), community-acquired bacterial pneumonia (CABP), urinary tract infections, and other serious community-acquired bacterial infections; and Sarecycline, a tetracycline-derived compound that is in Phase III clinical trials for the treatment of acne and rosacea.